



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/516,428	11/30/2004	Francis Chi	550/9-2011	4964
28156	7590	01/16/2008	EXAMINER	
COLEMAN SUDOL SAPONE, P.C. 714 COLORADO AVENUE BRIDGE PORT, CT 06605-1601			SZPERKA, MICHAEL EDWARD	
ART UNIT		PAPER NUMBER		
1644				
MAIL DATE		DELIVERY MODE		
01/16/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/516,428	CHI ET AL.	
	Examiner	Art Unit	
	Michael Szperka	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 25 October 2007.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-30,34,35 and 37-43 is/are pending in the application.
4a) Of the above claim(s) 1-23,27,28 and 43 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 24-26,29,30,34,35 and 37-42 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date. ____.
3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 5) Notice of Informal Patent Application
6) Other: ____.

DETAILED ACTION

1. Applicant's response and amendments received October 25, 2007 are acknowledged.

Claims 31-33 and 36 have been canceled.

Claims 24 and 25 have been amended.

Claims 1-30, 34, 35, and 37-43 are pending in the instant application.

Claims 1-23, 27, 28, and 43 stand withdrawn from consideration as being drawn to nonelected inventions and species. See 37 CFR 1.142(b) and MPEP § 821.03, for reasons of record set forth in the restriction requirement mailed October 11, 2005.

Claims 24-26, 29, 30, 34, 35, and 37-42 are under examination as they read on administering antibodies that bind adipocyte plasma membranes to reduce adipose tissue content.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. The rejection of claim 36 under 35 U.S.C. 112, second paragraph, has been rendered moot by applicant's cancellation of said claim.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

6. The rejection of claims 24-26 and 29-42 under 35 U.S.C. 103(a) as being obvious over Flint (US Patent No. 5,102,658, of record as reference AB on the IDS received 3/4/05, see entire document) in view of Lee (US patent No. 5,367,054, see entire document) has been withdrawn upon additional consideration. Arguments made by applicant that are applicable to other rejections will be addressed with said rejections.

7. Claims 24-26, 29, 30, 34, 35, and 37-42 are rejected under 35 U.S.C. 103(a) as being obvious over Flint (US Patent No. 5,102,658, of record as reference AB on the IDS received 3/4/05, see entire document) in view of Cryer et al. (US Patent 5,631,009) and in view of Lee (US patent No. 5,367,054, see entire document)

Flint discloses methods of administering antibodies raised against adipocyte plasma membranes to target animals in order to decrease adipose tissue mass in the target animal (see entire document, particularly the abstract, claims 1-3, and lines 19-23 of column 1). He further discloses that the administered antibodies can be made in an

animal that is evolutionarily removed from the target animal in which a decrease in adipose tissue is desired (see particularly lines 26-30 of column 1 and Example C). Note that in working example C, rats were administered anti-rat adipocyte plasma membrane polyclonal antibodies that had been made in sheep. Particularly desirable target animals for the treatment methods taught by Flint include humans, lambs, cows, and pigs (see particularly lines 19-23 of column 1 and claim 3). He further discloses that use of hybridoma technology allows for the large scale production of antibodies without the need for serum donors (see particularly lines 48-50 of column 1).

This disclosure differs from the instant claimed invention in that Flint does not specifically mention that egg laying animals are to be used to produce anti-adipocyte antibodies and Flint does not indicate that anti-adipocyte antibodies are to be orally administered.

Cryer et al. disclose methods for reducing body fat in animals by administering antibodies specific for adipocyte membranes (see entire document, particularly the abstract). Anti-adipocyte antibodies are disclosed as being passively administered by a variety of routes, including oral administration (see particularly lines 40-44 of column 4).

Lee discloses methods of producing large quantities of IgY antibodies from the yolk of chickens and other egg-laying animals such as reptiles, amphibians and fish (see entire document, particularly the abstract, lines 5-10 of column 1, and claims 1-15). Antibodies produced in eggs enjoy the advantages of increased specificity against mammalian proteins, low cost, convenience, and compatibility with animal welfare regulations (see particularly lines 34-47 of column 1). Additional advantages of egg yolk antibodies are that they can be easily administered in food and in other compositions suitable for oral ingestion (see particularly lines 29-33 of column 1 and lines 30-40 of column 3).

Therefore, a person of ordinary skill in the art at the time the invention was made would have been motivated to administer anti-adipocyte plasma membrane antibodies to a target animal to reduce adipose tissue mass in the target animal as taught by Flint by an oral route because Cryer et al. disclose that anti-adipocyte antibodies are to be

administered via an oral route to reduce adiposity. A person of ordinary skill in the art would have been further motivated to make such anti-adipocyte antibodies in egg laying animals, such as chickens, due to the advantages of high yield, low cost, increased specificity , and ability to be added to food for increased ease of administration as was disclosed by Lee. Note also that alterations in dosages, amounts, and timings of administered agents are routinely performed by ordinary artisans for the purpose of maximizing the therapeutic efficacy of any given treatment method. Further, the courts have held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 220 F2d 454,456,105 USPQ 233; 235 (CCPA 1955) and MPEP § 2144. For all of the above reasons, the instant claimed methods would have been *prima facie* obvious to a person of ordinary skill in the art at the time the instant invention was made.

Applicant's arguments filed October 25, 207 have been fully considered but they are not persuasive. Applicant argues that Flint does not disclose oral administration of anti-adipocyte antibodies.

Cryer et al. disclose that anti-adipocyte antibodies are to be administered orally.

Applicant next argues that Flint teaches away from the use of egg laying animals.

This argument is not persuasive. The disclosure of Flint is not limited to his working examples as applicant appears to be arguing. Claim 1 of Flint is not limited to administration of donor serum, and the specification clearly discloses hybridoma technology as an alternate source of large quantities of antibody for use in his methods. Lee discloses that large quantities of antibodies can be obtained from the yolk of eggs obtained from immunized egg laying animals, such as chickens. As such, a person of ordinary skill in the art would know from Flint's disclosure that large amounts of antibodies are needed to perform his methods and that large amounts of antibodies can be obtained from eggs as was disclosed by Lee.

Applicant also argues that a person of ordinary skill in the art would not combine the references because they are not analogous art, specifically that Flint discloses treatment methods whereas Lee discloses antibody purification.

This argument is not persuasive. The skill of an ordinary artisan in the biological sciences is quite high, with most practitioners holding advanced degrees such as an M.D. or Ph.D. degree. Such ordinary artisans who were practicing methods of antibody administration would be well versed in how antibodies can be made (since they obviously need to know how to make antibodies such that they can administer them) from a variety of sources and would not assume that only serum form donor animals would work. Indeed, as has been previously discussed, Flint explicitly discloses hybridoma technology as another means to produce the antibodies in his method. All of the cited references are readily within the purview and understanding of the ordinary artisan and as such would be readily combined by said ordinary artisan.

Applicant's final argument is that the examiner has improperly dismissed the effectiveness of orally ingested antibodies as was presented in Experiment II of the instant specification because a skilled artisan would not expect such a method to work at all.

This argument is not persuasive. As was stated in the prior office action, the evidence of Experiment II was considered but was not considered to be an effective secondary consideration to overcome the finding of legal obviousness. As was previously stated:

It appears that applicant is arguing unexpected results based upon the data presented in the specification as Experiment II beginning on page 25. In this experiment, rats were administered antibodies specific for pig adipocytes wherein the antibodies were produced in the egg of a chicken. The data indicate that rats that were orally administered antibody lost more weight than rats receiving antibody subcutaneously.

The reason that applicant's argument of unanticipated results is not persuasive is because a demonstration of unexpected results must be

commensurate in scope with that which is being claimed. In the instant situation, the claimed methods are not limited to the precise conditions disclosed in Experiment II, and thus the claimed methods are broader in scope than the experiment. If the results of experiment II are "unexpected", a skilled artisan would not reasonably expect that other conditions, such as the use of other source and target animals, or the use of antigen preparations prepared from other animals or prepared using methodologies other than the exact protocol used in the disclosed experiment, would have the same "unexpected" outcome. Further, the instant claimed methods do not recite any standard of efficacy, and as such the efficacy of oral versus subcutaneous administration is not particularly relevant since the claims have been rejected based upon the obviousness of orally administering anti-adipocyte antibodies made in eggs.

Note further that based upon the disclosure of Cryer et al., it is not unexpected that orally administered anti-adipocyte antibodies would work since Cryer et al. disclose oral administration as one of their treatment modalities.

8. No claims are allowable.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Szperka whose telephone number is 571-272-2934. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Michael Szperka, Ph.D.
Patent Examiner
Art Unit 1644
January 10, 2008